GD2 Targeted Therapies
2 drugsAbout GD2
GD2 is a disialoganglioside, a glycosphingolipid found on the surface of certain cells. Predominantly expressed in tumors, GD2 is an important oncology target.
GD2's expression on tumor cells and limited presence in normal tissues makes it an attractive target for antibody-based therapies. There is currently no genetic evidence directly linking GD2 to specific diseases.
Two FDA-approved drugs target GD2: UNITUXIN and DANYELZA. These drugs include one antibody and one biologic (other) therapeutic modality.
Top GD2 Drugs
Two companies, UNITED THERAP and Y-MABS THERAPEUTICS INC, have approved drugs targeting GD2.
The market is not highly competitive, suggesting opportunities for new entrants.
GD2 Drug Modality Landscape
Modalities
Routes of Administration
GD2 is exclusively targeted by antibodies, suggesting it may be a cell-surface or secreted protein.
Consider novel modalities beyond antibodies and biologics to differentiate from existing therapies.
📈 Modality Evolution
Antibodies pioneered GD2 targeting (2015), with other biologics entering more recently (2020).
GD2 Clinical Trials 47 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on GD2. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 16 | 3 | 1 | 12 | 75% |
| Phase 2 | 25 | 8 | 2 | 14 | 80% |
| Phase 3 | 5 | 1 | 0 | 4 | 100% |
| Phase 4 | 1 | 0 | 0 | 1 | - |
Top Sponsors
By Modality
Top Conditions
GD2 Drug Approval Timeline (2015 - 2020)
The first GD2-targeting drug was approved in 2015, with the most recent in 2020.
The relatively short approval span indicates potential for further innovation in this area.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 30 (5 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on GD2. A trial counts if an approved drug acting on GD2 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.